HYFTOR: How JPA Health Launched the First Approved Medicine for a Rare Genetic Disorder

Nobelpharma America turned to JPA Health to brand and launch its first U.S. product, HYFTOR®, the first topical treatment approved by the FDA for the treatment of facial angiofibroma (FA), a rare genetic disorder in children and adults with tuberous sclerosis complex (TSC).

The Impact


new prescribers
in two months





The Challenge

Facial angiofibroma was consistently deprioritized as a treatable condition, because of the overall complexity of TSC. Yet people living with facial angiofibroma experience significant impact from bullying, depression, and other emotional challenges.

We developed a memorable brand story that brought to life the product’s unique position in the market — and its benefits for patients, caregivers and HCPs. We gathered insights through market research with neurologists, dermatologists, patients, and caregivers.

The “my VICTORY” campaign brought to life how HYFTOR® answers the unmet needs of patients and their loved ones.


“my VICTORY” represented life beyond TSC/FA and patients’ ability to continue a normal life in the face of this rare disease. It showcased a sense of freedom to contrast with the stress and limitation that we found hinders patients, caregivers and HCPs.


The campaign included a full stable of paid, earned and owned assets created to build awareness of HYFTOR®. All elements created in support of the launch of HYFTOR® included print and digital versions of assets for patients, caregivers, HCPs and sales teams at Nobelpharma America.

Request a Proposal

Ready to make an impact? Let’s do this together.

"*" indicates required fields

Accepted file types: pdf, doc, docx, Max. file size: 5 MB.
Opt in to marketing emails
This field is for validation purposes and should be left unchanged.